TY  - JOUR
TI  - Prediction of Stem Cell Mobilization Failure in Patients with
Hodgkin and Non-Hodgkin Lymphoma
AB  - Objective: Autologous stem cell transplantation (ASCT) is a significant
and potentially curative treatment modality for patients with
relapsed/refractory lymphoma. Insufficient mobilization and harvest
of peripheral stem cells can be a major obstacle for performing ASCT.
The aim of this study was to evaluate the factors that might influence
mobilization failure in patients with lymphoma.
Materials and Methods: Eighty-seven patients diagnosed with
non-Hodgkin and Hodgkin lymphoma who underwent stem cell
mobilization afterwards at the Hacettepe University Medical School
Bone Marrow Transplantation Center, Turkey, between the years of
2000 and 2018 were evaluated.
Results: A total of 87 patients were included in this study. In 66 of 87
patients (75.9%), the first mobilization trial was successful. Adequate
(≥2x106/kg) CD34+ cells were collected in the first apheresis for 66
patients (9.5±8.1). For 21 of 87 (24.1%), the first mobilization trial was
unsuccessful. Therefore, a second mobilization trial was performed for
these patients with plerixafor (5.5±3.3). The number of CD34+ cells
was significantly higher in patients who were successful in the first
mobilization (p=0.002).
Conclusion: The success rate of the first mobilization trial was found
to be higher in patients with high platelet counts before mobilization
and patients who received chemotherapy-based mobilization
protocols. In the patients who had mobilization failure in the first
trial, plerixafor was used in a later mobilization, and those patients
had an adequate amount of stem cells for ASCT. Parameters predicting
mobilization failure would allow for preemptive, more cost-effective
use of such agents during the first mobilization attempt; however, risk
factors for mobilization failure are still not clea
AU  - BÜYÜKAŞIK, Yahya
AU  - GOKER, ALI HAKAN
AU  - Demiroglu, Haluk
AU  - Çiftçiler, Rafiye
DO  - 10.4274/tjh.galenos.2020.2020.0409
PY  - 2021
JO  - Turkish Journal of Hematology
VL  - 38
IS  - 3
SN  - 1300-7777
SP  - 204
EP  - 210
DB  - TRDizin
UR  - http://search/yayin/detay/508989
ER  -